Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis

Ying Liu, Jia He, Jingjing Jiang, Yujuan Wang, Ting Liu Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People’s Republic of ChinaCorrespondence: Ting Liu, Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South...

Full description

Bibliographic Details
Main Authors: Liu Y, He J, Jiang J, Wang Y, Liu T
Format: Article
Language:English
Published: Dove Medical Press 2022-12-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
Online Access:https://www.dovepress.com/reactive-arthritis-triggered-by-adalimumab-and-leflunomide-in-a-patien-peer-reviewed-fulltext-article-CCID
_version_ 1797985227380883456
author Liu Y
He J
Jiang J
Wang Y
Liu T
author_facet Liu Y
He J
Jiang J
Wang Y
Liu T
author_sort Liu Y
collection DOAJ
description Ying Liu, Jia He, Jingjing Jiang, Yujuan Wang, Ting Liu Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People’s Republic of ChinaCorrespondence: Ting Liu, Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Shunqing District, Nanchong, Sichuan Province, 637000, People’s Republic of China, Tel +8615082780013, Email 332656467@qq.comAbstract: Reactive arthritis (ReA) is uncommon. The present case is a Chinese man who has been treated with adalimumab and leflunomide to control ankylosing spondylitis (AS). During the treatment, the patient developed a range of symptoms, including fever, fatigue, pustular rash, suppurative urethritis, genital ulcers, oral ulcers, bilateral uveitis, heel pain and swelling and pain of the knee and ankle joints. The laboratory studies revealed the presence of HLA-B27, and urethral secretions were positive for Ureaplasma urealyticum. The patient was eventually diagnosed with ReA. The development of ReA may be related to the combination of adalimumab and leflunomide, which reduces immune function and triggers activation of potential U. urealyticum. The patient received 3 weeks of antibiotics, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), resulting in a significant improvement. The dose of corticosteroids was gradually reduced, and adalimumab was reintroduced. The patient was followed up for 3 months without recurrence.Keywords: reactive arthritis, Reiter syndrome, ankylosing spondylitis, urethritis, arthritis, uveitis, HLA-B27
first_indexed 2024-04-11T07:15:03Z
format Article
id doaj.art-f05ec0a583524a75a697a88b56405ae6
institution Directory Open Access Journal
issn 1178-7015
language English
last_indexed 2024-04-11T07:15:03Z
publishDate 2022-12-01
publisher Dove Medical Press
record_format Article
series Clinical, Cosmetic and Investigational Dermatology
spelling doaj.art-f05ec0a583524a75a697a88b56405ae62022-12-22T04:38:02ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-12-01Volume 152601260580034Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing SpondylitisLiu YHe JJiang JWang YLiu TYing Liu, Jia He, Jingjing Jiang, Yujuan Wang, Ting Liu Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People’s Republic of ChinaCorrespondence: Ting Liu, Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Shunqing District, Nanchong, Sichuan Province, 637000, People’s Republic of China, Tel +8615082780013, Email 332656467@qq.comAbstract: Reactive arthritis (ReA) is uncommon. The present case is a Chinese man who has been treated with adalimumab and leflunomide to control ankylosing spondylitis (AS). During the treatment, the patient developed a range of symptoms, including fever, fatigue, pustular rash, suppurative urethritis, genital ulcers, oral ulcers, bilateral uveitis, heel pain and swelling and pain of the knee and ankle joints. The laboratory studies revealed the presence of HLA-B27, and urethral secretions were positive for Ureaplasma urealyticum. The patient was eventually diagnosed with ReA. The development of ReA may be related to the combination of adalimumab and leflunomide, which reduces immune function and triggers activation of potential U. urealyticum. The patient received 3 weeks of antibiotics, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), resulting in a significant improvement. The dose of corticosteroids was gradually reduced, and adalimumab was reintroduced. The patient was followed up for 3 months without recurrence.Keywords: reactive arthritis, Reiter syndrome, ankylosing spondylitis, urethritis, arthritis, uveitis, HLA-B27https://www.dovepress.com/reactive-arthritis-triggered-by-adalimumab-and-leflunomide-in-a-patien-peer-reviewed-fulltext-article-CCIDreactive arthritisreiter syndromeankylosing spondylitisurethritisarthritisuveitishla-b27
spellingShingle Liu Y
He J
Jiang J
Wang Y
Liu T
Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
Clinical, Cosmetic and Investigational Dermatology
reactive arthritis
reiter syndrome
ankylosing spondylitis
urethritis
arthritis
uveitis
hla-b27
title Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
title_full Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
title_fullStr Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
title_full_unstemmed Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
title_short Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
title_sort reactive arthritis triggered by adalimumab and leflunomide in a patient with ankylosing spondylitis
topic reactive arthritis
reiter syndrome
ankylosing spondylitis
urethritis
arthritis
uveitis
hla-b27
url https://www.dovepress.com/reactive-arthritis-triggered-by-adalimumab-and-leflunomide-in-a-patien-peer-reviewed-fulltext-article-CCID
work_keys_str_mv AT liuy reactivearthritistriggeredbyadalimumabandleflunomideinapatientwithankylosingspondylitis
AT hej reactivearthritistriggeredbyadalimumabandleflunomideinapatientwithankylosingspondylitis
AT jiangj reactivearthritistriggeredbyadalimumabandleflunomideinapatientwithankylosingspondylitis
AT wangy reactivearthritistriggeredbyadalimumabandleflunomideinapatientwithankylosingspondylitis
AT liut reactivearthritistriggeredbyadalimumabandleflunomideinapatientwithankylosingspondylitis